Zentalis Pharmaceuticals Llc
$ 2.47
0.82%
24 Feb - close price
- Market Cap 158,639,000 USD
- Current Price $ 2.47
- High / Low $ 2.61 / 2.43
- Stock P/E N/A
- Book Value 3.50
- EPS -2.08
- Next Earning Report 2026-03-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.49 %
- 52 Week High 3.95
- 52 Week Low 1.01
About
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.
Analyst Target Price
$5.31
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-06 | 2025-05-05 | 2025-02-25 | 2024-11-04 | 2024-08-09 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-09 | 2023-05-10 | 2023-03-01 |
| Reported EPS | -0.37 | -0.37 | -0.67 | -0.6138 | -0.56 | -1.24 | 0.14 | -0.93 | -0.79 | -1.85 | -1.07 | -0.92 |
| Estimated EPS | -0.53 | -0.54 | -0.6069 | -0.6817 | -0.8708 | -0.84 | -0.77 | -0.92 | -0.91 | -1.04 | -1.02 | -1.06 |
| Surprise | 0.16 | 0.17 | -0.0631 | 0.0679 | 0.3108 | -0.4 | 0.91 | -0.01 | 0.12 | -0.81 | -0.05 | 0.14 |
| Surprise Percentage | 30.1887% | 31.4815% | -10.3971% | 9.9604% | 35.6913% | -47.619% | 118.1818% | -1.087% | 13.1868% | -77.8846% | -4.902% | 13.2075% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.41 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZNTL
2026-02-22 09:49:18
SVB Leerink has recognized Zentalis Pharmaceuticals' decision to prioritize its WEE1 drug (ZN-c3) and BCL-2 inhibitor (ZN-d5) programs, discontinuing others. While acknowledging potential investor disappointment regarding earlier assets, the analyst deems this strategic shift prudent, especially given AstraZeneca's termination of a competing WEE1 inhibitor. As a result of this narrowed focus and reduced R&D expenses, SVB Leerink has lowered Zentalis' price target by 37%, from $67 to $42.
2026-02-18 19:57:48
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical oncology innovator, announced that its management team will participate in three upcoming investor conferences in late February and early March 2026. These include the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the TD Cowen 45th Annual Health Care Conference, and the Leerink Partners Global Healthcare Conference. The company will discuss its lead investigational drug, azenosertib, a first-in-class WEE1 inhibitor targeting ovarian cancer.
2026-02-18 17:28:17
Zentalis Pharmaceuticals announced its participation in three upcoming investor conferences in February and March 2026, where management will engage in fireside discussions. These conferences include the Oppenheimer 36th Annual Healthcare Life Sciences Conference, TD Cowen 45th Annual Health Care Conference, and Leerink Partners Global Healthcare Conference. The company, a clinical oncology innovator focusing on its WEE1 inhibitor azenosertib for ovarian cancer, will provide webcast access to these events.
2026-02-18 17:28:17
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical oncology innovator, announced that its management will participate in three upcoming investor conferences in late February and March 2026. These include virtual and in-person fireside discussions at Oppenheimer, TD Cowen, and Leerink Partners. The company will discuss the late-stage development of its investigational first-in-class WEE1 inhibitor, azenosertib, for ovarian cancer.
2026-02-18 13:27:53
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced its participation in several upcoming investor conferences in February and March 2026. The company's management team will hold fireside discussions at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, TD Cowen 45th Annual Health Care Conference, and Leerink Partners Global Healthcare Conference. Zentalis is a clinical oncology innovator focusing on the late-stage development of azenosertib, a WEE1 inhibitor, for ovarian cancer and other tumor types.
2026-02-18 13:06:00
Zentalis Pharmaceuticals, Inc. announced its participation in three upcoming investor conferences in late February and early March 2026. Management will hold fireside discussions at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, TD Cowen 45th Annual Health Care Conference, and Leerink Partners Global Healthcare Conference. The company, an oncology innovator, is advancing its WEE1 inhibitor azenosertib for ovarian cancer.
